Cash is not an issue multiple chats on that last year - we are good well into the new fin year... and will announce small agile raises if necessary and as James mentioned last year from inflection point to inflection point - charts show the market rewards this approach.
we have had trials running concurrently over the last year - the longer they run the better for results as we have discussed many times
given some trials under way have been running for 12 months is a very very very good thing - each day brings us closer to results... ending trials prematurely generally indicates an issue.
no one has been able to offer another example of an ASX listed company with a compound in so many trials most with collaborations with esteemed research companies.
KZA Price at posting:
61.0¢ Sentiment: Buy Disclosure: Held
